NCT06724263View on ClinicalTrials.gov

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical CancersSmall Cell Lung CancerHepatocellular Carcinoma (HCC)Colorectal CancerNon-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

B1962

B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

lead

Tasly Biopharmaceuticals Co., Ltd.

INDUSTRY